BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

851 related articles for article (PubMed ID: 35530162)

  • 1. Emerging role of natural products in cancer immunotherapy.
    Dong S; Guo X; Han F; He Z; Wang Y
    Acta Pharm Sin B; 2022 Mar; 12(3):1163-1185. PubMed ID: 35530162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological drug and drug delivery-mediated immunotherapy.
    Xiao Q; Li X; Li Y; Wu Z; Xu C; Chen Z; He W
    Acta Pharm Sin B; 2021 Apr; 11(4):941-960. PubMed ID: 33996408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
    Yang M; Li J; Gu P; Fan X
    Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of PD-1 Blockade in Cancer Immunotherapy.
    Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
    Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy.
    Draghiciu O; Lubbers J; Nijman HW; Daemen T
    Oncoimmunology; 2015 Jan; 4(1):e954829. PubMed ID: 25949858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer.
    Shrimali D; Shanmugam MK; Kumar AP; Zhang J; Tan BK; Ahn KS; Sethi G
    Cancer Lett; 2013 Dec; 341(2):139-49. PubMed ID: 23962559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice.
    Stamatopoulos A; Stamatopoulos T; Gamie Z; Kenanidis E; Ribeiro RDC; Rankin KS; Gerrand C; Dalgarno K; Tsiridis E
    J Bone Oncol; 2019 Jun; 16():100231. PubMed ID: 30956944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer.
    Sun D; Zou Y; Song L; Han S; Yang H; Chu D; Dai Y; Ma J; O'Driscoll CM; Yu Z; Guo J
    Acta Pharm Sin B; 2022 Jan; 12(1):378-393. PubMed ID: 35127393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solute carrier transporters: the metabolic gatekeepers of immune cells.
    Song W; Li D; Tao L; Luo Q; Chen L
    Acta Pharm Sin B; 2020 Jan; 10(1):61-78. PubMed ID: 31993307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the MIR155 host gene in physiological and pathological processes.
    Elton TS; Selemon H; Elton SM; Parinandi NL
    Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy using a polysaccharide from
    Park HB; Lim SM; Hwang J; Zhang W; You S; Jin JO
    Oncoimmunology; 2020 Jun; 9(1):1772663. PubMed ID: 32923129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
    Maccalli C; Parmiani G; Ferrone S
    Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
    Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
    Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory mechanisms of bioactive milk proteins in the intestine of newborns.
    Chatterton DE; Nguyen DN; Bering SB; Sangild PT
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1730-47. PubMed ID: 23660296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment.
    Zhang J; Fan J; Zeng X; Nie M; Luan J; Wang Y; Ju D; Yin K
    Acta Pharm Sin B; 2021 Mar; 11(3):609-620. PubMed ID: 33777671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance.
    Lee BC; Lee J
    Biochim Biophys Acta; 2014 Mar; 1842(3):446-62. PubMed ID: 23707515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.